LM-101 was well tolerated. The preliminary efficacy signal supports further evaluation of LM-101 plus rituximab in relapsed/refractory lymphoma.
LM-101, an anti-SIRPα antibody, in patients with relapsed/refractory lymphoma and advanced head and neck cancer: an open-label, multicenter, phase 1 trial
Jun Cai·Qingqing Cai·D M Ji·Fuling Zhou·Shenrui Bai·Xiaojie Fang·Man Nie·Bing Bai·Yuchen Zhang·Jin Li·Haoyuan Li·Yuan Li·Da Fei·Xia Qin·Crystal Qin·Shuiyu Zhao·Yi Xia·Baitian Zhao